The US Bioresorbable Polymers Market is driven by advancements in medical technology and a growing focus on patient-centric care. As these polymers find increasing application in fields such as orthopedics, drug delivery, and tissue engineering, the market is expected to expand at a robust CAGR of 11.2% from 2024 to 2035. The market size was valued at USD 1,080 Million in 2025 and is anticipated to reach approximately USD 3,360 Million by 2035.
The economic impact of tariffs on "US Bioresorbable Polymers Market".
Market Growth Drivers
Increasing Adoption in Orthopedic Applications: Companies such as Evonik Industries AG have developed bioresorbable polymers specifically for orthopedic implants, leading to improved patient outcomes due to reduced risks of chronic inflammation and elimination of secondary surgeries. The expanding geriatric population and rising incidence of bone-related disorders have significantly fueled demand for these advanced materials in bone fixation devices, screws, and pins, further boosting market growth.
Technological Advancements in Drug Delivery: Major players like Corbion N.V. are innovating new grades of polylactic acid (PLA) and polyglycolic acid (PGA) copolymers, enabling more effective and controlled drug release profiles. The biocompatibility and tailored degradation rates of these polymers offer superior therapeutic benefits, driving their adoption for targeted and minimally invasive therapies in the US healthcare sector.
Market Trends
Focus on Sustainable Medical Solutions: Companies such as Ashland Global Holdings are shifting towards greener solutions by enhancing the sustainability profile of bioresorbable polymers. This trend is largely influenced by regulatory pressures and growing environmental concerns within the healthcare industry, leading to eco-friendly alternatives gaining traction in wound care and surgical devices.
Integration of 3D Printing Technologies: The incorporation of 3D printing by companies like DSM Biomedical has revolutionized the customization of implants and scaffolds made from bioresorbable polymers. The capability to precisely fabricate patient-specific devices is improving treatment efficacy, promoting faster adoption of personalized medicine in the US market.
Market Opportunities
Expansion into Dental and Maxillofacial Applications: Companies like Poly-Med, Inc. are exploring the use of bioresorbable polymers for advanced dental membrane barriers and facial reconstruction devices, providing new revenue streams and growth opportunities in the market.
Strategic Collaborations for R&D: Enhanced partnerships between polymer manufacturers and healthcare providers are accelerating the development of next-generation bioresorbable materials, driving innovation and commercialization of novel devices in the US.
US Bioresorbable Polymers Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates a strong upward trajectory from 2020 through 2035. In 2020, the market size stood at USD 420 Million and gradually increased each year due to technological advancements and expanding application areas. By 2025, revenue had reached USD 1,080 Million, reflecting significant investment and commercial adoption. The upward trend continues with accelerated growth in the next decade, ultimately reaching USD 3,360 Million by 2035. This sustained trajectory underscores growing demand and innovation throughout the forecast period.
US Bioresorbable Polymers Market by Regions Share (%), 2025
In 2025, the Northeastern US dominates the bioresorbable polymers market, capturing 36% of the total market share, owing to the concentration of major medical device manufacturers and research institutions. The Midwest holds a 23% share, driven by a robust healthcare sector and infrastructure. The West region, accounting for 20%, shows strong growth due to its dynamic biotech startups and innovation hubs. The South secures 15%, while other regions contribute 6%, reflecting emerging adoption rates and growth potential for future years.
US Bioresorbable Polymers Market Recent Developments
In February 2024, DSM Biomedical announced the commercial launch of a new line of high-strength bioresorbable polymers designed for load-bearing orthopedic applications. The product aims to replace traditional metal implants, reduce the need for surgical removal, and enhance patient recovery times. The company’s partnership with leading US hospitals and medical device OEMs is accelerating clinical validation and rapid market entry.
In March 2024, Corbion N.V. expanded its R&D capabilities in the US by inaugurating a dedicated research center in Boston, focused on innovative bioresorbable materials for controlled drug delivery. The center will collaborate with local universities and biotech companies, advancing the next generation of custom-tailored polymer solutions for challenging medical applications.
In May 2024, Evonik Industries AG introduced a new grade of polyglycolide-co-lactide copolymers to the market. The new product features tunable degradation rates and enhanced mechanical properties, intended for use in vascular stents and tissue engineering scaffolds in the US. The launch follows successful FDA clearance and initial contracts with major US-based medical device manufacturers.
Press Releases